Literature DB >> 12612881

The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.

Mary Beth Beasley1, Sylvie Lantuejoul, Susan Abbondanzo, Wei-Sing Chu, Philip S Hasleton, William D Travis, Elizabeth Brambilla.   

Abstract

Rb protein in its hypophosphorylated form acts as a cell cycle regulator for G1 arrest. Both cyclin D1 overexpression and P16(INK4) loss of protein produce persistent hyperphosphorylation of Rb with resultant evasion of cell cycle arrest. To better establish the mechanisms of loss of Rb function in neuroendocrine lung tumors, we performed an immunohistochemical analysis of the P16(INK4)/cyclin D1/Rb pathway in the spectrum of neuroendocrine tumors, including 34 typical carcinoids (TCs), 25 atypical carcinoids (ACs), 42 large cell neuroendocrine carcinomas (LCNECs), and 79 small cell lung carcinomas (SCLCs). Absence of Rb expression was not observed in TCs but was seen in 21% of ACs, 68% of LCNECs, and 87% of SCLCs. P16 was expressed in 91% of TCs, 77% of ACs, 78% of LCNECs, and 93% of SCLCs. Cyclin D1 was overexpressed in 6% of TCs, 20% of ACs, 9.5% of LCNECs, and 1.3% of SCLCs. There was an inverse relationship between Rb and P16 in high-grade tumors (P < 0.001) and a direct relationship between cyclin D1 and Rb (P < 0.001) in all tumors, demonstrating that P16 and cyclin D1 act exclusively on the Rb pathway for cell cycle regulation. Overall, the Rb pathway (Rb/P16(INK4)/cyclin D1) was altered more frequently in ACs than in TCs (P = 0.001) and more frequently in LCNECs than in ACs (P = 0.001). Although Rb-negative tumors had shorter survival in the overall group (P < 0.001) as a result of lack of Rb in most SCLCs, cyclin D1 overexpression and P16 loss did not influence survival in any individual category. We conclude that Rb pathway of G1 arrest is consistently compromised in high-grade neuroendocrine lung tumors (92%), primarily through loss of Rb protein, and is intact in low-grade TCs. In ACs an intermediate level of alterations (59%) is seen, consistent with their less-aggressive behavior compared with high-grade tumors. The specific profile of the Rb pathway parameters might provide specific therapeutic targets in neuroendocrine lung tumors. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612881     DOI: 10.1053/hupa.2003.8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

1.  A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Authors:  Giuseppe Pelosi; Aldo Scarpa; Giulia Veronesi; Lorenzo Spaggiari; Barbara Del Curto; Patrick S Moore; Patrick Maisonneuve; Angelica Sonzogni; Michele Masullo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-13       Impact factor: 4.064

Review 2.  Therapeutic biomarkers in lung neuroendocrine neoplasia.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Simona Vatrano; Giuseppe Pelosi; Mauro Papotti
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 3.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

Review 4.  Human Papillomavirus-Related Neuroendocrine Carcinomas of the Head and Neck.

Authors:  William H Westra
Journal:  Head Neck Pathol       Date:  2018-03-20

Review 5.  Cellular and molecular biology of small cell lung cancer: an overview.

Authors:  Niki Karachaliou; Sara Pilotto; Chiara Lazzari; Emilio Bria; Filippo de Marinis; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 6.  Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma-An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin.

Authors:  Rebecca D Chernock; Eric J Duncavage
Journal:  Head Neck Pathol       Date:  2018-03-20

7.  MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Authors:  Liqin Du; Jeoffrey J Schageman; Luc Girard; Scott M Hammond; John D Minna; Adi F Gazdar; Alexander Pertsemlidis
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

Review 8.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

9.  Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status.

Authors:  Elizabeth D Thompson; Edward B Stelow; Stacey E Mills; William H Westra; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

Review 10.  Tracing the cellular origin of cancer.

Authors:  Cédric Blanpain
Journal:  Nat Cell Biol       Date:  2013-01-20       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.